14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Interplay between coronavirus, a cytoplasmic RNA virus, and nonsense-mediated mRNA decay pathway

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          Coronaviruses (CoVs) are important pathogens for humans and domestic animals. The development of effective countermeasures against CoVs requires an understanding of the host pathways that regulate viral gene expression and the viral subversion mechanisms. However, little is known about how the stability of viral mRNAs is controlled. We show that the nonsense-mediated decay (NMD) pathway, which primarily targets aberrant cellular mRNAs for degradation, also induced the degradation of CoV mRNAs that are of cytoplasmic origin. Our study further suggests the importance of CoV-induced inhibition of the NMD pathway, mediated by a viral protein, for efficient CoV replication. The present study highlights an interplay between the NMD pathway and CoVs that modulates viral replication by controlling the stability of viral mRNAs.

          Abstract

          Coronaviruses (CoVs), including severe acute respiratory syndrome CoV and Middle East respiratory syndrome CoV, are enveloped RNA viruses that carry a large positive-sense single-stranded RNA genome and cause a variety of diseases in humans and domestic animals. Very little is known about the host pathways that regulate the stability of CoV mRNAs, which carry some unusual features. Nonsense-mediated decay (NMD) is a eukaryotic RNA surveillance pathway that detects mRNAs harboring aberrant features and targets them for degradation. Although CoV mRNAs are of cytoplasmic origin, the presence of several NMD-inducing features (including multiple ORFs with internal termination codons that create a long 3′ untranslated region) in CoV mRNAs led us to explore the interplay between the NMD pathway and CoVs. Our study using murine hepatitis virus as a model CoV showed that CoV mRNAs are recognized by the NMD pathway as a substrate, resulting in their degradation. Furthermore, CoV replication induced the inhibition of the NMD pathway, and N protein (a viral structural protein) had an NMD inhibitory function that protected viral mRNAs from rapid decay. Our data further suggest that the NMD pathway interferes with optimal viral replication by degrading viral mRNAs early in infection, before sufficient accumulation of N protein. Our study presents clear evidence for the biological importance of the NMD pathway in controlling the stability of mRNAs and the efficiency of replication of a cytoplasmic RNA virus.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats.

          Although the finding of severe acute respiratory syndrome coronavirus (SARS-CoV) in caged palm civets from live animal markets in China has provided evidence for interspecies transmission in the genesis of the SARS epidemic, subsequent studies suggested that the civet may have served only as an amplification host for SARS-CoV. In a surveillance study for CoV in noncaged animals from the wild areas of the Hong Kong Special Administration Region, we identified a CoV closely related to SARS-CoV (bat-SARS-CoV) from 23 (39%) of 59 anal swabs of wild Chinese horseshoe bats (Rhinolophus sinicus) by using RT-PCR. Sequencing and analysis of three bat-SARS-CoV genomes from samples collected at different dates showed that bat-SARS-CoV is closely related to SARS-CoV from humans and civets. Phylogenetic analysis showed that bat-SARS-CoV formed a distinct cluster with SARS-CoV as group 2b CoV, distantly related to known group 2 CoV. Most differences between the bat-SARS-CoV and SARS-CoV genomes were observed in the spike genes, ORF 3 and ORF 8, which are the regions where most variations also were observed between human and civet SARS-CoV genomes. In addition, the presence of a 29-bp insertion in ORF 8 of bat-SARS-CoV genome, not in most human SARS-CoV genomes, suggests that it has a common ancestor with civet SARS-CoV. Antibody against recombinant bat-SARS-CoV nucleocapsid protein was detected in 84% of Chinese horseshoe bats by using an enzyme immunoassay. Neutralizing antibody to human SARS-CoV also was detected in bats with lower viral loads. Precautions should be exercised in the handling of these animals.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia

            The source of human infection with Middle East respiratory syndrome coronavirus remains unknown. Molecular investigation indicated that bats in Saudi Arabia are infected with several alphacoronaviruses and betacoronaviruses. Virus from 1 bat showed 100% nucleotide identity to virus from the human index case-patient. Bats might play a role in human infection.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The economic burden of non-influenza-related viral respiratory tract infection in the United States.

              Viral respiratory tract infection (VRTI) is the most common illness in humans. Despite the high incidence, the economic impact of non-influenza-related VRTI has not been rigorously explored. Our objectives were to obtain an updated incidence of non-influenza-related VRTI in the United States and to quantify the health care resource use (direct costs) and productivity losses (indirect costs) associated with these infections. A nationwide telephone survey of US households (N = 4051) was conducted between November 3, 2000, and February 12, 2001 to obtain a representative estimate of the self-reported incidence of non-influenza-related VRTI and related treatment patterns. Direct treatment costs measured included outpatient clinician encounters, use of over-the-counter and prescription drugs, and associated infectious complications of non-influenza-related VRTI. Absenteeism estimates for infected individuals and parents of infected children were extrapolated from National Health Interview Survey data. Of survey respondents, 72% reported a non-influenza-related VRTI within the past year. Respondents who experienced a self-reported non-influenza-related VRTI averaged 2.5 episodes annually. When these rates are extrapolated to the entire US population, approximately 500 million non-influenza-related VRTI episodes occur per year. Similarly, if the treatment patterns reported by the respondents are extended to the population, the total economic impact of non-influenza-related VRTI approaches $40 billion annually (direct costs, $17 billion per year; and indirect costs, $22.5 billion per year). Largely because of the high attack rate, non-influenza-related VRTI imposes a greater economic burden than many other clinical conditions. The pending availability of effective antiviral therapies warrants increased attention be paid to this common and expensive illness.
                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc. Natl. Acad. Sci. U.S.A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                23 October 2018
                8 October 2018
                8 October 2018
                : 115
                : 43
                : E10157-E10166
                Affiliations
                [1] aDepartment of Microbiology and Immunology, The University of Texas Medical Branch , Galveston, TX 77555-1019;
                [2] bCenter for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch , Galveston, TX 77555-1019;
                [3] cCenter for Tropical Diseases, The University of Texas Medical Branch , Galveston, TX 77555-1019;
                [4] dSealy Center for Vaccine Development, The University of Texas Medical Branch , Galveston, TX 77555-1019;
                [5] eInstitute for Human Infections and Immunity, The University of Texas Medical Branch , Galveston, TX 77555-1019
                Author notes
                2To whom correspondence should be addressed. Email: shmakino@ 123456utmb.edu .

                Edited by Paul Ahlquist, University of Wisconsin–Madison, Madison, WI, and approved September 19, 2018 (received for review July 6, 2018)

                Author contributions: S.M. designed research; M.W., K.G.L., K. Nakagawa, and K. Narayanan performed research; M.W. and S.M. analyzed data; and M.W., K. Narayanan, and S.M. wrote the paper.

                1M.W. and K.G.L. contributed equally to this work.

                Article
                201811675
                10.1073/pnas.1811675115
                6205489
                30297408
                eef8227e-1365-4b35-baa5-d2c3b41d4e07
                Copyright © 2018 the Author(s). Published by PNAS.

                This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

                History
                Page count
                Pages: 10
                Funding
                Funded by: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 100000060
                Award ID: AI99107
                Award Recipient : Shinji Makino
                Funded by: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 100000060
                Award ID: AI114657
                Award Recipient : Shinji Makino
                Funded by: UT | University of Texas Medical Branch at Galveston (UTMB) 100008013
                Award ID: Pilot grant from the Institute for Human Infections and Immunity
                Award Recipient : Keisuke Nakagawa Award Recipient : Shinji Makino
                Funded by: UT | University of Texas Medical Branch at Galveston (UTMB) 100008013
                Award ID: The James W. McLaughlin fellowship fund
                Award Recipient : Keisuke Nakagawa Award Recipient : Shinji Makino
                Categories
                530
                PNAS Plus
                Biological Sciences
                Microbiology
                PNAS Plus
                Custom metadata
                free

                nonsense-mediated mrna decay,cytoplasmic rna virus,coronavirus,inhibition of nmd,long 3′ utr

                Comments

                Comment on this article